Late Stage Hepatitis C

Andy Slaughter Excerpts

Tuesday 6th January 2015 Westminster Hall

[Stephen Pound (Ealing North) (Lab)]

I am sure that I speak for everyone present when I say that it is an honour to be before you, Mr Gray. Let me also say that if I could have chosen any Minister to respond to this debate, it would have been the Minister who is here, because her record in this field, as in many others, is exemplary. I am delighted to be able to raise these points in such company.

Hepatitis C is something that is still a mystery to a large number of people. Most people know that in the classical Greek, hepatitis refers to the fire in the blood, and it is considered to be one of those blood-borne diseases of which we know very little because of the multiplicity of presentations. In fact, hepatitis C, the subject of today’s debate, was originally referred to as hepatitis non-A or B, because nobody knew exactly what it was. However, we now know what it is, and it is a great tragedy that today 215,000 people are chronically affected by hepatitis C in the United Kingdom. Of that number, 160,000 are in England.

The majority of patients have become infected through exposure to contaminated blood in various ways. I know that some hon. Members present wish to raise the issue of blood contamination in the health service, but in many cases, where it comes from is not as significant today as where we are going with it. A whole range of issues lead to contraction of hepatitis C.

[Mr Andy Slaughter (Hammersmith) (Lab)]

I am very pleased that my hon. Friend has obtained this debate. Unfortunately, my constituency has a high prevalence of hepatitis C. He mentioned contaminated blood —I know he wants to talk about other issues—and 30,000 people have been infected since the 1970s through contaminated NHS blood products. Perhaps, like me, he hopes that the Minister will say something about that and whether there will be a final settlement before the general election—whether something will finally be done to help those people who suffer from this disease through no fault of their own, but through negligence by Government.

[Stephen Pound]

I profoundly endorse my hon. Friend’s comments and I very much hope that what he refers to will be the outcome. It is a cruel irony if one presents at a hospital in search of good health, and ends up iller than when one went in. I certainly will refer to that later.

One of the highest levels of hepatitis C infection in this country is from injecting drugs. That is part of the stereotype, and it is the case that 49% of identified hepatitis C cases in England, 34% in Northern Ireland and 33% in Wales are from that source. There are significant public health risks of further transmission if hepatitis C is left untreated. This is the astonishing and terrifying aspect of hepatitis C, and if we achieve nothing else today, we can at least ventilate the issue and, I hope, bring it to the attention of a few more people in the country. Hepatitis C is one of the most sinister blood-borne diseases, in that it in effect lies dormant for 20 to 30 years in the blood. A person who lived a fairly rackety life in the 1960s may have no idea that they have been infected with hepatitis C. It may present itself 30 years later, when the symptoms of lassitude, fatigue, inexplicable tiredness lead the individual to go and see their medical practitioner; and it is a simple blood test—it does not require anything other than a spot of blood on a piece of paper—that reveals it. The sinister, long-standing, dormant nature of hepatitis C is something to which I wish to refer.

--- Later in debate ---

[The Parliamentary Under-Secretary of State for Health (Jane Ellison)]

It is a pleasure to serve under your chairmanship, Mr Gray. I thank the hon. Member for Ealing North (Stephen Pound) for his kind words and congratulate him on securing this important debate. Hepatitis is a significant health issue that has been overshadowed by others for too long, in part because of many of the people who are most affected, so I welcome this opportunity to discuss it. In nine minutes I cannot possibly respond to all the points that have been made, so I will say straight away that I am going to put the issue of contaminated blood to one side as there will probably be another debate on that at some point. Work is ongoing with regard to previous problems with contaminated blood in the NHS. We are still awaiting the findings of Lord Penrose’s much delayed inquiry, which, as it addresses pre-devolution issues, is highly relevant. Nevertheless, I must put that issue to one side.

[Mr Slaughter]

Will the Minister give way?

[Jane Ellison]

I cannot take an intervention on that point because I must deal with the rest of the debate.

On presumed consent, within the past year we have had two good, thorough debates in this Chamber on issues of organ donation and consent. It is a very interesting area of discussion. I am watching the Welsh experience with interest; I do not dismiss it, but it is very complex. I would be happy to debate it at any time with any Member because it is a topic to which I have given quite a lot of thought and consideration.

I pay tribute to the Hepatitis C Trust for its work. More recently, I have met the Hepatitis C Coalition, which has impressed on me with great force some of the issues that it wishes to see addressed—issues that were picked up by the hon. Member for Ealing North.

The NICE appraisal of the first of the new hep C therapies is due very soon, so this debate is timely. Understandably a lot of the focus is on the new therapies, but focus on prevention runs right through the NHS long-term strategy. That is highly relevant because if people are to be treated with good, new and expensive therapies, it is important to address issues such as re-infection rates and good public health prevention. Members should be in no doubt about the Government’s commitment, which I suspect would be shared by any Government, to reducing the big killers—the main reasons for premature mortality in our country—one of which is liver disease. We cannot tackle the big killers if we are not tackling hepatitis C. We are clear that the contribution that tackling hepatitis C can make to reducing current rates of end-stage liver disease is an important part of any premature mortality strategy.